RT Journal Article
T1 Engineered pH-Responsive Mesoporous Carbon Nanoparticles for Drug Delivery
A1 Gisbert Garzarán, Miguel
A1 Berkmann, Julia C.
A1 Giasafaki, Dimitra
A1 Lozano Borregón, Daniel
A1 Spyrou, Konstantinos
A1 Manzano García, Miguel
A1 Steriotis, Theodore
A1 Duda, Georg N.
A1 Schmidt-Bleek, Katharina
A1 Charalambopoulou, Georgia
A1 Vallet Regí, María Dulce Nombre
AB In this work, two types of mesoporous carbon particles with different morphology, size, and pore structure have been functionalized with a self-immolative polymer sensitive to changes in pH and tested as drug nanocarriers. It is shown that their textural properties allow significantly higher loading capacity compared to typical mesoporous silica nanoparticles. In vial release experiments of a model Ru dye at pH 7.4 and 5 confirm the pH-responsiveness of the hybrid systems, showing that only small amounts of the cargo are released at physiological pH, whereas at slightly acidic pH (e.g., that of lysosomes), self-immolation takes place and a significant amount of the cargo is released. Cytotoxicity studies using human osteosarcoma cells show that the hybrid nanocarriers are not cytotoxic by themselves but induce significant cell growth inhibition when loaded with a chemotherapeutic drug such as doxorubicin. In preparation of an in vivo application, in vial responsiveness of the hybrid system to short-term pH-triggering is confirmed. The consecutive in vivo study shows no substantial cargo release over a period of 96 h under physiological pH conditions. Short-term exposure to acidic pH releases an experimental fluorescent cargo during and continuously after the triggering period over 72 h.
SN 1944-8244
YR 2020
FD 2020-03-06
LK https://hdl.handle.net/20.500.14352/95821
UL https://hdl.handle.net/20.500.14352/95821
LA eng
NO Gisbert-Garzarán M, Berkmann JC, Giasafaki D, Lozano D, Spyrou K, Manzano M, et al. Engineered pH-Responsive Mesoporous Carbon Nanoparticles for Drug Delivery. ACS Appl Mater Interfaces 2020;12:14946–57. https://doi.org/10.1021/acsami.0c01786.
NO Horizon 2020
NO European Research Council
DS Docta Complutense
RD 5 abr 2025